Openbookopenbook
Equity
Shin Nippon Biomedical Laboratories, Ltd.(SBLOF)
USD --+0.00%
Reward58Moderate
Risk53Moderate
📊75%Data
3.7% dividend yield · Revenue down 34% YoY
SBLOF
+0.0 · +0.00%
USD · PINK
Shin Nippon Biomedical Laboratories, Ltd. | Healthcare
Dividend King
Market Cap:389.67M
ℹ️
Reward Rating
58
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
53
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on SBLOF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Shin Nippon Biomedical Laboratories, Ltd.?

, a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally.

SBLOF · Verdict

Solid reward · elevated risk

SBLOF stands out on volatility and growth, but watch the balance sheet signal.

Based on 88% data coverage

SBLOF · Verdict

What’s working & what to watch

Strengths 3

  • Volatility75/100

    Above average

  • Growth67/100

    Rev +22.2% CAGR · earnings -11.6%

  • Cash flow66/100

    -12% free-cash-flow margin

Watchouts 2

  • Balance sheet13/100

    Current ratio 1.13

  • Valuation45/100

    In line with peers

Model-based scoring. For information only — not financial advice.

What is Shin Nippon Biomedical Laboratories, Ltd.?

, a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 389.67M, and a P/E ratio of 11.7x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (58)

The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap389.67M
P/E Ratio11.7
Dividend Yield3.73%
52 Week High16.1411
52 Week Low9.0455
Last AnnualMarch
IPO DateN/A
IncorporatedUSA
Shares Outstanding42M
No. of Employees1,532
IndustryDiagnostics & Research
ExchangePINK
Beta-0.448
CurrencyUSD · Reports in JPY
Websitewww.snbl.co.jp
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.